Last reviewed · How we verify
Toclizumab
Toclizumab is a Small molecule drug developed by Weill Medical College of Cornell University. It is currently in discontinued development. Also known as: ACTEMRA®.
Tocilizumab is a medication used to treat glucocorticoid-refractory acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. It is administered as part of a Phase II clinical study (NCT01757197) to evaluate its effectiveness in this specific condition.
At a glance
| Generic name | Toclizumab |
|---|---|
| Also known as | ACTEMRA® |
| Sponsor | Weill Medical College of Cornell University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Toclizumab CI brief — competitive landscape report
- Toclizumab updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI
Frequently asked questions about Toclizumab
What is Toclizumab?
Who makes Toclizumab?
Is Toclizumab also known as anything else?
What development phase is Toclizumab in?
Related
- Manufacturer: Weill Medical College of Cornell University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: ACTEMRA®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing